Introduction:
Post-operative nausea and vomiting (PONV) is a common complication after anesthesia and surgery, leading to distress and potential complications. Ramosetron, a newer 5-HT3 receptor antagonist, has shown to have more potent and longer-lasting antiemetic effects compared to first-generation 5-HT3 receptor antagonists like ondansetron. This study aimed to compare the efficacy of ramosetron and ondansetron for preventing PONV in patients undergoing laparoscopic cholecystectomy under general anesthesia.
Methods:
A total of 120 patients aged 18-60 years, falling under ASA I-II category and scheduled for laparoscopic cholecystectomy, were included in this observational analytical cohort study after obtaining informed consent. Group I received intravenous ramosetron 0.3 mg, while Group II received intravenous ondansetron 4 mg at the time of extubation. The standard general anesthetic technique was used, and postoperative incidences of nausea, vomiting, and complications were recorded at 1, 2, 6, and 24 hours after surgery.
Results:
There were no significant demographic differences between the groups. The percentage of patients with a complete response (no PONV and no need for additional rescue antiemetic) from 0 to 24 hours after anesthesia was 96.7% with ramosetron and 83.3% with ondansetron. Both drugs showed comparable safety profiles, as no clinically serious adverse effects were observed in either group.
Conclusion:
Prophylactic therapy with ramosetron was found to be more effective than ondansetron in preventing PONV in patients undergoing laparoscopic cholecystectomy under general anesthesia.
Post-operative nausea and vomiting (PONV) is a common complication after anesthesia and surgery, leading to distress and potential complications. Ramosetron, a newer 5-HT3 receptor antagonist, has shown to have more potent and longer-lasting antiemetic effects compared to first-generation 5-HT3 receptor antagonists like ondansetron. This study aimed to compare the efficacy of ramosetron and ondansetron for preventing PONV in patients undergoing laparoscopic cholecystectomy under general anesthesia.
Methods:
A total of 120 patients aged 18-60 years, falling under ASA I-II category and scheduled for laparoscopic cholecystectomy, were included in this observational analytical cohort study after obtaining informed consent. Group I received intravenous ramosetron 0.3 mg, while Group II received intravenous ondansetron 4 mg at the time of extubation. The standard general anesthetic technique was used, and postoperative incidences of nausea, vomiting, and complications were recorded at 1, 2, 6, and 24 hours after surgery.
Results:
There were no significant demographic differences between the groups. The percentage of patients with a complete response (no PONV and no need for additional rescue antiemetic) from 0 to 24 hours after anesthesia was 96.7% with ramosetron and 83.3% with ondansetron. Both drugs showed comparable safety profiles, as no clinically serious adverse effects were observed in either group.
Conclusion:
Prophylactic therapy with ramosetron was found to be more effective than ondansetron in preventing PONV in patients undergoing laparoscopic cholecystectomy under general anesthesia.
